Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelics and Anti-inflammatory Activity in Animal Models
Thomas W. Flanagan, Charles D. Nichols
Current topics in behavioral neurosciences (2022), pp. 229-245
Closed Access | Times Cited: 20

Showing 20 citing articles:

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 33
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Bryan Barksdale, Manoj K. Doss, Gregory A. Fonzo, et al.
Neurotherapeutics (2024), pp. e00322-e00322
Open Access | Times Cited: 13
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics
Antonella Campanale, Antonio Inserra, Stefano Comai
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111058-111058
Open Access | Times Cited: 6
The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
Stephan Tap
Addiction Biology (2024) Vol. 29, Iss. 4
Open Access | Times Cited: 5
Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers
Juliana Lima Constantino, Jens H. van Dalfsen, Sara Massetti, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025) Vol. 136, pp. 111251-111251
Open Access
Psychedelics in neuroinflammation: Mechanisms and therapeutic potential
Júnia L. de Deus, Juliana Marino Maia, Renato Nery Soriano, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111278-111278
Closed Access
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Ellen Bradley, Kimberly Sakai, Gisele Fernandes‐Osterhold, et al.
Neuropsychopharmacology (2025)
Open Access
5-HT2A Receptors: Pharmacology and Functional Selectivity
Benjamin Cummins, Gerald Billac, David E. Nichols, et al.
Pharmacological Reviews (2025), pp. 100059-100059
Closed Access
Disruptive Psychopharmacology
Frederick S. Barrett, Katrin H. Preller
Current topics in behavioral neurosciences (2022)
Closed Access | Times Cited: 17
Psychedelics and schizophrenia: a double-edged sword
Jacopo Sapienza, Francesca Martini, Stefano Comai, et al.
Molecular Psychiatry (2024)
Closed Access | Times Cited: 3
Bedside to bench: the outlook for psychedelic research
Victor P. Acero, Emily S. Cribas, Kevin D. Browne, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression
Thomas W. Flanagan, Timothy P. Foster, Thomas E. Galbato, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 2, pp. 478-492
Open Access | Times Cited: 2
Single administration of a psychedelic [(R)-DOI] influences coping strategies to an escapable social stress
Kevin T. Krupp, Jazmine D.W. Yaeger, Leighton J. Ledesma, et al.
Neuropharmacology (2024) Vol. 252, pp. 109949-109949
Open Access | Times Cited: 1
Chemistry/structural biology of psychedelic drugs and their receptor(s)
Ryan H. Gumpper, David E. Nichols
British Journal of Pharmacology (2024)
Closed Access | Times Cited: 1
Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum
Geoffrey M. Bove, David J. Mokler
Journal of Psychedelic Studies (2022) Vol. 6, Iss. 3, pp. 171-175
Open Access | Times Cited: 6
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: An Open-Label Pilot Trial
Ellen Bradley, Kimberly Sakai, Gisele Fernandes‐Osterhold, et al.
(2024)
Closed Access
The Therapeutic Effects of Classic Psychedelics in Alcohol Use Disorder
Broc A. Pagni, Jonathan M. Wong, Michael P. Bogenschutz
Current Addiction Reports (2024) Vol. 11, Iss. 5, pp. 916-927
Closed Access
Depressive Disorders
Hymie Anisman, Shawn Hayley, Alexander W. Kusnecov
Immune system (2024), pp. 229-267
Closed Access
References

Immune system (2024), pp. 471-578
Closed Access
Psychedelic and nutraceutical interventions as therapeutic strategies for military-related mild traumatic brain injuries
Amy C. Reichelt, Eric Vermetten, Benjamin T. Dunkley
Journal of Military Veteran and Family Health (2023) Vol. 9, Iss. 5, pp. 28-37
Closed Access | Times Cited: 1
Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress
Noah D. Gold, Samantha K. Podrebarac, Lindsay A. White, et al.
Psychedelic Medicine (2023) Vol. 1, Iss. 2, pp. 87-97
Closed Access
Page 1

Scroll to top